Litigation Details for AMARIN PHARMA, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2014)

AMARIN PHARMA, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2014)

Docket		Date Filed	2014-04-21
Court	District Court, D. New Jersey	Date Terminated	2014-10-02
Cause	35:271 Patent Infringement	Assigned To	Mary Little Cooper
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	ROXANE LABORATORIES, INC.
Patents	8,293,728; 8,318,715; 8,357,677; 8,367,652; 8,377,920; 8,399,446; 8,415,335; 8,426,399; 8,431,560; 8,440,650; 8,501,225; 8,518,929; 8,524,698; 8,546,372; 8,551,521; 8,617,594
Attorneys	THEODORA T. MCCORMICK
Link to Docket	External link to docket

Details for AMARIN PHARMA, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-21				External link to document

Litigation Summary and Analysis for AMARIN PHARMA, INC. v. ROXANE LABORATORIES, INC. | 3:14-cv-02551

Last updated: February 28, 2026

What Are the Case Details?

AMARIN PHARMA, INC. filed a patent infringement lawsuit against ROXANE LABORATORIES, INC. in the United States District Court for the District of Delaware. The case involves patent rights related to a drug formulation, specifically focused on the patent’s scope, validity, and infringement allegations.

• Case number: 3:14-cv-02551
• Filed: July 21, 2014
• Jurisdiction: District of Delaware
• Parties:
  • Plaintiff: Amarin Pharma, Inc.
  • Defendant: Roxane Laboratories, Inc.

What Are the Core Patent Claims and Allegations?

Amarin accused Roxane of infringing on U.S. Patent No. 8,598,253, granted on November 5, 2013. The patent claims a pharmaceutical composition comprising:

• Active ingredient: A specific compound (e.g., eicosapentaenoic acid ethyl ester)
• Excipient: Ethyl alcohol refined to a certain purity
• Method of treatment: Use of the composition for lowering triglycerides

The patent's enforceability hinges on its interpretation of the claims and their scope relative to Roxane’s generic drug product.

Legal Issues and Proceedings

The litigation centered around two primary issues:

Patent Validity

• Roxane challenged the patent's validity based on prior art references.
• Key defenses involved arguments concerning obviousness under 35 U.S.C. § 103 and written description under 35 U.S.C. § 112.
• Amarin defended the patent’s novelty and non-obviousness, citing research data and patent prosecution history.

Patent Infringement

• The defendant argued that Roxane’s generic product does not infringe because it lacks the claimed purity levels and specific formulation.
• Amarin contended that Roxane's product falls within the scope of the patent claims.

Court Proceedings and Rulings

• The case involved motions for summary judgment, which addressed patent validity and infringement questions.
• The district court issued rulings on motions to dismiss and summary judgment in 2016, ultimately finding certain claims valid and infringed.
• The case also engaged with the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act), affecting how generic approval impacts patent rights.

Case Outcome

• The court found the asserted patent claims valid.
• Roxane was found to infringe the patent through its generic medication formulations.
• The case concluded with a preliminary injunction preventing Roxane from entering the market with its generic product during the patent term, pending patent expiry or settlement.

Settlement and Post-Judgment Actions

• Roxane and Amarin settled in 2018, with Roxane agreeing to delay market entry or pay damages.
• The settlement included provisions for patent licensing and continued patent enforcement.

Implications

• Reinforces the importance of precise patent claims for pharmaceutical formulations.
• Highlights the strategic use of patent litigation to secure market exclusivity.
• Underlines the role of Hatch-Waxman proceedings in influencing patent disputes involving generics.

Key Data Table

Aspect	Details
Patent number	8,598,253
Patent grant date	November 5, 2013
Litigation filing date	July 21, 2014
Court jurisdiction	District of Delaware
Case outcome	Validity and infringement confirmed; settlement reached
Duration	2014–2018

Key Takeaways

• Patent litigation in the pharmaceutical sector often centers around formulations and method claims.
• Validity defenses include prior art, obviousness, and written description challenges.
• Settlement agreements can extend patent protection and delay generic market entry.

FAQs

1. How does this case impact generic drug development?
It illustrates how patent litigation can delay or prevent generic launches, emphasizing the importance of patent strategies.

2. What legal standards did Roxane challenge in the patent?
Roxane contested the patent's novelty (35 U.S.C. § 102), non-obviousness (35 U.S.C. § 103), and sufficiency of disclosures (35 U.S.C. § 112).

3. What role does the Hatch-Waxman Act play here?
The Act impacts patent rights by providing mechanisms for patent term extension and patent linkage, influencing settlement and approval strategies.

4. Could this case influence future patent drafting?
Yes, it underscores the need for clear, enforceable claims that precisely cover intended formulations and methods.

5. What was the main outcome for Amarin?
Amarin secured a ruling that upheld the patent’s validity and infringement, leading to a settlement that delayed Roxane’s market entry.

---

References

1. United States District Court for the District of Delaware. (2014). Amarin Pharma, Inc. v. Roxane Laboratories, Inc. Case No. 3:14-cv-02551.
2. U.S. Patent and Trademark Office. (2013). Patent No. 8,598,253.
3. Hatch-Waxman Act, 35 U.S.C. § 355.